Inspire Medical Systems, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Inspire reported Q2 2026 revenue of $200.6M (down 7.6% YoY, primarily due to U.S. coding/reimbursement headwinds), with adjusted diluted EPS of $0.14. The company raised full-year 2026 guidance to $835–875M revenue and adjusted EPS of $1.05–1.45. Management announced "Project Horizon," a strategic restructuring expected to incur $20–25M in pre-tax charges (including $4–5M employee costs, $16–20M non-cash) to generate approximately $30M in annualized growth investment capacity. Cash position strengthened to $415.2M as of June 30, 2026, with operating cash flow of $23.2M in Q2.
Why this rating
Restructuring and guidance raise are moderate—$30M capacity on $3.8B market cap is ~0.8% of company value. Revenue growth headwinds partially offset by margin expansion and cost control; execution risk on Project Horizon unclear.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.